Incyte 8-K, filed Jul 28, 2026

Summary

Incyte reported second-quarter 2026 total revenue of $1.67 billion and total net sales of $1.49 billion, up 38% and 40% respectively from a year earlier, and raised its full-year 2026 total net sales guidance to $5.13–$5.26 billion, citing a CMS agreement covering Opzelura's line extension and continued growth of its hematology and oncology products. Chief Executive Bill Meury said the quarter included the acquisition of latarcibart (formerly VGA039), a Phase 3 von Willebrand disease candidate, and the company expects ten clinical data readouts in the second half of 2026.

Key points

• Jakafi/Jakafi XR net sales were $817 million, up 7% from the prior-year period; Opzelura net sales were $450 million, up 173%, or $204 million and up 24% excluding a one-time, non-cash $246 million CMS-related benefit.
• Full-year 2026 Opzelura net sales guidance rose to $1.05–$1.10 billion and hematology and oncology net sales guidance to $860–$890 million; Jakafi guidance was unchanged at $3.22–$3.27 billion.
• Total 2026 operating expense guidance was raised to $4.92–$5.00 billion GAAP, reflecting an approximately $1.27 billion IPR&D expense expected in the third quarter from the Vega Therapeutics acquisition and $50 million of incremental latarcibart R&D.
• Global regulatory submissions for Monjuvi/Minjuvi in newly diagnosed DLBCL were accepted in the second quarter, with a potential U.S. approval and launch anticipated in the first quarter of 2027.

Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.